Transcatheter Aortic Valve Replacement for Aortic Valve Disease
Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,000 (estimated)
- Sponsor
- Xijing Hospital · Other
This trial is looking for patients with aortic valve disease who are suitable for a procedure called TAVR. Participants will have their health data collected before, during, and after the procedure for up to 10 years to monitor outcomes.
You may be able to join if
- I have been diagnosed with aortic valve disease
- I have been evaluated by a cardiac team and can have TAVR
- I understand the purpose of this study
- I am willing to participate in the trial and sign the consent form
You may not be able to join if
- I have been told by a cardiac team that I cannot have TAVR
- I cannot tolerate the materials or medications used in this study
- I am pregnant or breastfeeding
- I have participated in another clinical trial for a drug or device recently
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this prospective multi-center, observational registry in China is to collect clinical baseline, procedural, and follow-up data of all patients treated with TAVR in China and to evaluate short-, mid-, and long-term clinical outcome data of all post-marketing transcatheter valves. Each center will collect baseline and procedural data as well as clinical outcomes for up to 10 years.
Loading trial locations…